Valproate as an adjunct to antipsychotics for schizophrenia: A systematic review of randomized trials

Anja Basan; Werner Kissling; Stefan Leucht

doi:10.1016/j.schres.2004.01.016

Valproate as an adjunct to antipsychotics for schizophrenia: A systematic review of randomized trials

Anja Basan
, Werner Kissling
, Stefan Leucht

Klinik und Poliklinik für Psychiatrie und Psychotherapie

Technische Universität München
Zucker Hillside Hospital

Publikation: Beitrag in Fachzeitschrift › Artikel › Begutachtung

58 Zitate (Scopus)

Abstract

Randomized controlled trials comparing valproate (as a sole, or as an adjunctive compound) to placebo for patients with schizophrenia or schizophrenia-like disorders were summarized in a metaanalysis. It was possible to include only five trials (n=379) examining valproate as add-on to antipsychotics in this review. Some of the single studies showed inconsistent beneficial effects on some aspects of response, but no overall superiority of valproate augmentation at study endpoints was shown.

Originalsprache	Englisch
Seiten (von - bis)	33-37
Seitenumfang	5
Fachzeitschrift	Schizophrenia Research
Jahrgang	70
Ausgabenummer	1
DOIs	https://doi.org/10.1016/j.schres.2004.01.016
Publikationsstatus	Veröffentlicht - 1 Sept. 2004

Zugriff auf Dokument

10.1016/j.schres.2004.01.016

Andere Dateien und Links

Verknüpfung zur Publikation in Scopus

Dieses zitieren

@article{d51fb377264d47cb858f00f4c6432f0f,

title = "Valproate as an adjunct to antipsychotics for schizophrenia: A systematic review of randomized trials",

abstract = "Randomized controlled trials comparing valproate (as a sole, or as an adjunctive compound) to placebo for patients with schizophrenia or schizophrenia-like disorders were summarized in a metaanalysis. It was possible to include only five trials (n=379) examining valproate as add-on to antipsychotics in this review. Some of the single studies showed inconsistent beneficial effects on some aspects of response, but no overall superiority of valproate augmentation at study endpoints was shown.",

keywords = "Add-on treatment, Metaanalysis, Schizophrenia, Valproate, Valproid acid",

author = "Anja Basan and Werner Kissling and Stefan Leucht",

note = "Funding Information: The authors wish to thank the editorial team of the Cochrane schizophrenia group, under the auspices of which the review was undertaken (Basan et al., 2003) . The work is part of the German Research Network on Schizophrenia and was funded by the German Federal Ministry for Education and Research BMBF (grant 01 GI 993x).",

year = "2004",

month = sep,

day = "1",

doi = "10.1016/j.schres.2004.01.016",

language = "English",

volume = "70",

pages = "33--37",

journal = "Schizophrenia Research",

issn = "0920-9964",

publisher = "Elsevier B.V.",

number = "1",

}

TY - JOUR

T1 - Valproate as an adjunct to antipsychotics for schizophrenia

T2 - A systematic review of randomized trials

AU - Basan, Anja

AU - Kissling, Werner

AU - Leucht, Stefan

N1 - Funding Information: The authors wish to thank the editorial team of the Cochrane schizophrenia group, under the auspices of which the review was undertaken (Basan et al., 2003) . The work is part of the German Research Network on Schizophrenia and was funded by the German Federal Ministry for Education and Research BMBF (grant 01 GI 993x).

PY - 2004/9/1

Y1 - 2004/9/1

N2 - Randomized controlled trials comparing valproate (as a sole, or as an adjunctive compound) to placebo for patients with schizophrenia or schizophrenia-like disorders were summarized in a metaanalysis. It was possible to include only five trials (n=379) examining valproate as add-on to antipsychotics in this review. Some of the single studies showed inconsistent beneficial effects on some aspects of response, but no overall superiority of valproate augmentation at study endpoints was shown.

AB - Randomized controlled trials comparing valproate (as a sole, or as an adjunctive compound) to placebo for patients with schizophrenia or schizophrenia-like disorders were summarized in a metaanalysis. It was possible to include only five trials (n=379) examining valproate as add-on to antipsychotics in this review. Some of the single studies showed inconsistent beneficial effects on some aspects of response, but no overall superiority of valproate augmentation at study endpoints was shown.

KW - Add-on treatment

KW - Metaanalysis

KW - Schizophrenia

KW - Valproate

KW - Valproid acid

UR - https://www.scopus.com/pages/publications/3142713738

U2 - 10.1016/j.schres.2004.01.016

DO - 10.1016/j.schres.2004.01.016

M3 - Article

C2 - 15246461

AN - SCOPUS:3142713738

SN - 0920-9964

VL - 70

SP - 33

EP - 37

JO - Schizophrenia Research

JF - Schizophrenia Research

IS - 1

ER -

Valproate as an adjunct to antipsychotics for schizophrenia: A systematic review of randomized trials

Abstract

Zugriff auf Dokument

Andere Dateien und Links

Fingerprint

Dieses zitieren